Paper36726367
Triple therapy in COPD: understanding the data.
Suissa S. ERJ Open Res, 2023. Cited by 16 papers, by iCite.
Cite this record
ConductScience Library. Triple therapy in COPD: understanding the data. Papers, record 36726367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36726367
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References18
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33252985 | Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. | Am J Respir Crit Care Med | 2021 | https://conductscience.org/library/papers/33252985 | PubMed |
| 2 | 30545959 | Triple therapy trials in COPD: a precision medicine opportunity. | Eur Respir J | 2018 | https://conductscience.org/library/papers/30545959 | PubMed |
| 3 | 29669218 | Making Sense of Triple Inhaled Therapy for COPD. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29669218 | PubMed |
| 4 | 29668352 | Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29668352 | PubMed |
| 5 | 36065315 | Single-Inhaler Triple versus Dual Bronchodilator Therapy in COPD: Real-World Comparative Effectiveness and Safety. | Int J Chron Obstruct Pulmon Dis | 2022 | https://conductscience.org/library/papers/36065315 | PubMed |
| 6 | 32579807 | Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32579807 | PubMed |
| 7 | 30091348 | Single-Inhaler Triple versus Dual Therapy in Patients with COPD. | N Engl J Med | 2018 | https://conductscience.org/library/papers/30091348 | PubMed |
| 8 | 28642311 | Run-in bias in randomised trials: the case of COPD medications. | Eur Respir J | 2017 | https://conductscience.org/library/papers/28642311 | PubMed |
| 9 | 32584168 | The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial. | Am J Respir Crit Care Med | 2020 | https://conductscience.org/library/papers/32584168 | PubMed |
| 10 | 10922423 | Low-dose inhaled corticosteroids and the prevention of death from asthma. | N Engl J Med | 2000 | https://conductscience.org/library/papers/10922423 | PubMed |
| 11 | 29429593 | Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. | Lancet | 2018 | https://conductscience.org/library/papers/29429593 | PubMed |
| 12 | 27959688 | Real-World Evidence - What Is It and What Can It Tell Us? | N Engl J Med | 2016 | https://conductscience.org/library/papers/27959688 | PubMed |
| 13 | 35512458 | Relationship between prior inhaled corticosteroid use and benefits ofbudesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study. | Respir Med | 2022 | https://conductscience.org/library/papers/35512458 | PubMed |
| 14 | 32162970 | Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. | Am J Respir Crit Care Med | 2020 | https://conductscience.org/library/papers/32162970 | PubMed |
| 15 | 34569408 | Triple Therapy in COPD: Time for Adaptive Selection Trials. | COPD | 2021 | https://conductscience.org/library/papers/34569408 | PubMed |
| 16 | 30846476 | Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. | Eur Respir J | 2019 | https://conductscience.org/library/papers/30846476 | PubMed |
| 17 | 34126054 | Perplexing mortality data from triple therapy trials in COPD. | Lancet Respir Med | 2021 | https://conductscience.org/library/papers/34126054 | PubMed |
| 18 | 28767357 | Evidence for Health Decision Making - Beyond Randomized, Controlled Trials. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28767357 | PubMed |
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42513564 | Comparative Real-World Effectiveness of Fixed-Dose Triple Therapy Regimens in COPD: A Retrospective Cohort Study. | J Clin Med | 2026 | https://conductscience.org/library/papers/42513564 | PubMed |
| 40569182 | Chronic Obstructive Pulmonary Disease and Inhaled Treatment Effects on Mortality in Patients with Lung Cancer. | Ann Am Thorac Soc | 2025 | https://conductscience.org/library/papers/40569182 | PubMed |
| 40391556 | Patient response and remission in respiratory disease: Special focus on severe asthma and chronic obstructive pulmonary disease. | J Int Med Res | 2025 | https://conductscience.org/library/papers/40391556 | PubMed |
| 40076807 | Molecular Approaches to Treating Chronic Obstructive Pulmonary Disease: Current Perspectives and Future Directions. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40076807 | PubMed |
| 39191649 | Emulating randomized trials by observational database studies: the RCT-DUPLICATE initiative in COPD and asthma. | Am J Epidemiol | 2025 | https://conductscience.org/library/papers/39191649 | PubMed |
| 39189263 | The Current Molecular and Cellular Landscape of Chronic Obstructive Pulmonary Disease (COPD): A Review of Therapies and Efforts towards Personalized Treatment. | Proteomes | 2024 | https://conductscience.org/library/papers/39189263 | PubMed |
| 38626371 | Optimizing Pharmacotherapy Management of Chronic Obstructive Pulmonary Disease: Don't Miss the Forest for the Trees. | Am J Respir Crit Care Med | 2024 | https://conductscience.org/library/papers/38626371 | PubMed |
| 38397432 | Inhaled Corticosteroids in Subjects with Chronic Obstructive Pulmonary Disease: An Old, Unfinished History. | Biomolecules | 2024 | https://conductscience.org/library/papers/38397432 | PubMed |
| 38337438 | Comorbidities in COPD: Current and Future Treatment Challenges. | J Clin Med | 2024 | https://conductscience.org/library/papers/38337438 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36726367
GET https://conductscience.org/api/papers/v1/36726367/authors